Magnolia Capital Advisors LLC Buys New Stake in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Magnolia Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 29,500 shares of the company’s stock, valued at approximately $87,000. Magnolia Capital Advisors LLC owned 0.07% of DiaMedica Therapeutics at the end of the most recent reporting period.

Separately, Vanguard Group Inc. lifted its position in DiaMedica Therapeutics by 26.3% during the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after purchasing an additional 211,351 shares during the period. 10.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer restated an “outperform” rating and set a $6.00 target price on shares of DiaMedica Therapeutics in a research report on Friday, August 16th.

DiaMedica Therapeutics Stock Performance

Shares of DiaMedica Therapeutics stock opened at $4.19 on Tuesday. The firm has a 50-day simple moving average of $3.85 and a two-hundred day simple moving average of $3.18. The company has a market cap of $179.09 million, a P/E ratio of -7.48 and a beta of 1.47. DiaMedica Therapeutics Inc. has a fifty-two week low of $1.94 and a fifty-two week high of $4.95.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. During the same quarter last year, the company posted ($0.16) earnings per share. Equities research analysts forecast that DiaMedica Therapeutics Inc. will post -0.6 EPS for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.